Cutting Edge: Antitumor Immunity by Pathogen-Specific CD8 T Cells in the Absence of Cognate Antigen Recognition

J Immunol. 2020 Mar 15;204(6):1431-1435. doi: 10.4049/jimmunol.1901172. Epub 2020 Feb 12.

Abstract

Cancer prognosis often correlates with the number of tumor-infiltrating CD8 T cells, but many of these cells recognize pathogens that commonly infect humans. The contribution of pathogen-specific "bystander" CD8 T cells to antitumor immunity remains largely unknown. Inflammatory cytokines are sufficient for memory CD8 T cell activation and gain of effector functions, indicating tumor-derived inflammation could facilitate pathogen-specific CD8 T cells to participate in tumor control. In this study, we show in contrast to tumor-specific CD8 T cells that pathogen-specific primary memory CD8 T cells inside tumor were not able to exert their effector functions and influence tumor progression. However, infection-induced memory CD8 T cells with defined history of repeated Ag encounters (i.e., quaternary memory) showed increased sensitivity to tumor-derived inflammation that resulted in activation, gain of effector functions, and better control of tumor growth. Thus, memory CD8 T cells with heightened ability to recognize environmental inflammatory stimuli can contribute to antitumor immunity in the absence of cognate Ag recognition.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antigens, Viral / administration & dosage
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology
  • Bacterial Vaccines / administration & dosage
  • Bacterial Vaccines / genetics
  • Bacterial Vaccines / immunology
  • Cell Line, Tumor / transplantation
  • Disease Models, Animal
  • Disease Progression
  • Female
  • Glycoproteins / administration & dosage
  • Glycoproteins / genetics
  • Glycoproteins / immunology
  • Humans
  • Immunologic Memory*
  • Listeria monocytogenes / immunology
  • Lymphocyte Activation
  • Lymphocytes, Tumor-Infiltrating / immunology*
  • Lymphocytic choriomeningitis virus / immunology
  • Male
  • Mice
  • Mice, Transgenic
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / genetics
  • Peptide Fragments / immunology
  • T-Lymphocytes, Cytotoxic / immunology*
  • Tumor Microenvironment / immunology*
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / genetics
  • Vaccines, Attenuated / immunology
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology
  • Viral Proteins / administration & dosage
  • Viral Proteins / genetics
  • Viral Proteins / immunology

Substances

  • Antigens, Viral
  • Bacterial Vaccines
  • Glycoproteins
  • Peptide Fragments
  • Vaccines, Attenuated
  • Vaccines, Synthetic
  • Viral Proteins
  • glycoprotein peptide 33-41, Lymphocytic choriomeningitis virus